Our analyses in 3263 AA T2DM-ESRD cases and non-diabetic, non-nephropathy controls revealed an approximate 25–30% increase in DN risk with multiple FRMD3 SNPs in subjects not homozygous for the MYH9 E1 risk haplotype (or APOL1 risk variants). This evidence concerns the gene MYH9 and liver dysplastic nodule.